Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| PureTech Health plc | SPT-300 (Glyph allopregnanolone; formerly LYT-300) | Healthy volunteers, neurological and neuropsychological conditions | Phase 2a | Data Released | Oral | Neurology |
| Purple Biotech Ltd. | CM24 and OPDIVO (nivolumab) | 2L metastatic pancreatic cancer (PDAC) | Phase 2 | Data Released | Intravenous | Oncology |
| Purple Biotech Ltd. | NT219 in combination with cetuximab | Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) | Phase 2 | Ongoing | Intravenous | Oncology |
| Pyxis Oncology Inc. | Sotigalimab (PYX-107) | Oncology | Phase 2 | Ongoing | Intravenous | Oncology |
| Q32 Bio Inc. | ADX-097 | Renal Diseases | Phase 2 | Trial Discontinued | Intravenous | N/A |
| Q32 Bio Inc. | Bempikibart - (SIGNAL-AA) | Alopecia areata (AA) | Phase 2a | Enrollment Conclusion | Intravenous | Immunology |
| Quantum Biopharma Ltd. | FSD-F2R6-A-CP (unbuzzd) | Acute Alcohol Intoxication | ANDA Filing | Ongoing | Oral | Psychiatric |
| Quantum Biopharma Ltd. | Lucid-21-302 - (Lucid-MS) | Healthy Volunteers, multiple sclerosis | Phase 2 | Trial Planned | Oral | Neurology |
